PDL BioPharma Inc

PDL BioPharma — Debt Investor Presentation (November 2016)

26 slides from PDL BioPharma's debt investor presentation, Nov 15, 2016

  1. Slide 1: Convertible Notes Offering

    PDL Convertible Notes Offering November 2016

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements PDL This presentation contains forward-looking statements, including PDI’s expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. A

  3. Slide 3: PDL Disclaimers

    PDL Disclaimers Q This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weigh

  4. Slide 4: Overview

    PDL Overview

  5. Slide 5: PDL Mission

    PDL Mission PDL BioPharma seeks to optimize its return on investments so as to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries.

  6. Slide 6: PDL Today: Specialty Pharma, Royalty & Debt Deals

    Specialty Pharma Royalty & Debt Deals PDL Today Four debt deals representing deployed and committed capital of $268 and $308 million, respectively: Lensar, Direct Flow Medical, kaléo, and CareView. Seven royalty transactions representing deployed and committed capital of $496 and $537 million, respe

  7. Slide 7: PDL Future

    PDL PDL Future ¥ Acquiring additional specialty pharma products for Noden Pharma DAC. Specialty Pharma Y Significant focus. v Using proceeds from completed deals to fund new product acquisiti Royalty & Debt Deals Fewer royalty still fewer debt transactio Data from Eli Lilly’s Phase 3 trial in patien

  8. Slide 8: Experienced Leadership

    POL Experienced Leadership Management Board of Directors John McLaughlin Paul Edick President & CEO David Gryska OWE eecl Conesel & Jody Lindell Secretary John McLaughlin Peter Garcia Samuel Saks VP & Chief Financial Officer Paul Sandman Danny Hart Harold E. Selick, Ph.D. VP, Business Development Le

  9. Slide 9: Noden Pharma

    PDL NODEN y PHARMA

  10. Slide 10: Hypertension

    PDL Hypertension Q Chronic condition with serious long-term cardiovascular implications which affects about 29% of the US adult population = 78 million in US alone. Q Majority of hypertension diagnosis and management occurs in primary care setting (PCP) with rare referrals when there are severe co-m

  11. Slide 11: Tekturna Products in Noden

    PDL Tekturna Products in Noden a US = Tekturna® - aliskiren is a direct renin inhibitor for the treatment of hypertension that reduces plasma renin by inhibiting the conversion of angiotensinogen to angiotensin |. © Not for use with ACEs or ARBs in patients with diabetes or renal impairment, © Appro

  12. Slide 12: Noden Entities and Team

    PDL Noden Entities and Team Q Noden DAC * Domiciled in Ireland. * Responsible for development and commercialization activities worldwide. * Responsible for bulk tablet manufacture worldwide and fill-and-finish ex-US. Q Noden US * Domiciled in Delaware. * Responsible for commercialization in US. * Re

  13. Slide 13: Transition from Novartis

    PDL Transition from Novartis Q Commercialization » US o Novartis distributing through September 30, 2016 and Noden receiving a transfer of profit. o Noden USA assumed commercialization responsibilities on October 1, 2016. = Ex-US o Novartis distributing until transfer of marketing authorizations (pr

  14. Slide 14: Novartis/Tekturna Deal

    PDL Novartis/Tekturna Deal Q Total Potential Size = Up to $334 million. QO Closing Payments = $110 million to Novartis. = $40 million to Noden as working capital. O First Anniversary = $89 million due to Novartis. Q Milestones = Up to $95 million based on sales levels and generic competition. O Fina

  15. Slide 15: Tekturna IP

    PDL Tekturna IP Q Tekturna is protected by multiple patents covering composition of matter, pharmaceutical formulation and methods of manufacture. Q United States = Composition of matter protection to July 2018 for Tekturna; listed in the Orange Book; possible extension for 6 months with successful

  16. Slide 16: Tekturna: Market Research

    PDL Tekturna: Market Research Q Novartis = No active sales or marketing efforts with respect to Tekturna products for last 3 years. Q Market Research = 21 in-depth qualitative interviews with PCPs, cardiologists, hypertension specialists, and payers. = 209 participated in quantitative survey of PCPs

  17. Slide 17: Royalty & Debt Investments

    PDL Royalty & Debt Investments

  18. Slide 18: Royalty & Debt Investments

    PDL Rovalty Acquisition J kybella $8,500,000 “uly 2016 Royalty Acquisition 16 Royalty & Debt Investments Senior Secured Royalty Acquisition RIAD Upt0 $10,000,000 ‘uly 2015, Financing cane $40,000,000 ‘une 2015 ured Nowe $15,500,000 “tune 2018 ‘$150,000.00 ‘April2018 DIRECT FLO\ MEDICAL $53,000,000 N

  19. Slide 19: On-Going Transactions

    PDL On-Going Transactions Entity Deal Summary Entity Deal Summary FP xybetia * $25milionforanindvdua’srovaty kal * S150M innotes backed by 20% net sles f Auv- and 10% of net + 81 milion milestone upon attainment of specified sales evel EO sates oFeVzI0 by algo. Te Notes pay interest at 13% with an e

  20. Slide 20: Potential Royalty: Solanezumab

    PDL Potential Royalty: Solanezumab Solanezumab + Humanized antibody targeting beta amyloid, which is believed to cause Alzheimer’s Disease, designed by PDL and being developed by Eli Lilly. Previous Phase 3 Trials + In 2012, Lilly reported that ts initial Phase 3 trials in patients with mild and mod

  21. Slide 21: Investment Track Record

    PDL Investment Track Record Cash 4x Cash Cash Return Transaction Maturity Total © Amount Received Return (Money _Pre-Taxed Date Date Committed Invested _byPDL___(Years)__ Multiple) __IRR% Merus Labs Jul-2012 Sep-2013 $ 55.0 $ 54.6 $ 60.2 42 11 15.1% AxoGen* Oct-2012 Nov-2014 20.8 26.4 40.0 2.2 1s 24

  22. Slide 22: Financials

    PDL Financials

  23. Slide 23: Income Statements

    PDL Income Statements ‘Three Months Ended Nine Months Ended ‘September 30, September 30, \(in thousands, except per share amounts) (unaudited) 2016 2015 2016 2015 Royalties from Queen et al. patents $ 14958 _$ 119222 _$ 150,645 _$ 363.916 Royalty rights - change in fair value 16,085 (4280) (11.872)

  24. Slide 24: Condensed Balance Sheets

    PDL Condensed Balance Sheets Condensed consolidated balance sheets (unaudited) September 30, December 31, Cash, cash equivalents and investments Total notes receivable Total royalty rights - at fair value Total term loan payable Convertible notes payable 1:2 $ $ $ Total assets $1,216,066 $ $ $ Total

  25. Slide 25: Conclusion

    PDL Conclusion

  26. Slide 26: Investment Highlights

    PDL Investment Highlights Q Tekturna and Tekturna HCT are important unique products for treatment of hypertension with potential upside in revenues if promoted appropriately. QO Noden is a tax efficient vehicle and additional spec pharma products will be added. QO 16 royalty and debt deals with 11 o

PDL BioPharma — Debt Investor Presentation (November 2016) on 6ix